Table 1 Population characteristics.
| Â | FD-PASS in-silico trial | ASPIRe7 | PREMIER8 | |
|---|---|---|---|---|
Number of aneurysms | 82 | 109 | 207 | 141 |
Age, year | Â | Â | Â | Â |
Mean ± SD (N) | 54.6 ± 9.6 (82) | 57.0 ± 11.3 (108) | 59.9 ± 12.5 (191) | 54.6 ± 11.3 (141) |
Median | 50.0 | 59.0 | 60.0 | Â |
Range | 36.0–85.0 | 30.2–75.0 | 25.0–89.0 |  |
Female sex, % (n/N) | 78.0 (64/82) | 88.9 (96/108) | 83.8 (160/191) | 87.9 (124/141) |
Hypertension, % (n/N) | – | 55.6 (60/108) | 53.9 (103/191) | 51.1 (72/141) |
Aneurysm size, mm | Â | Â | Â | Â |
Mean ± SD (N) | 9.1 ± 4.0 (82) | 18.2 ± 6.5 (82) | 14.5 ± 6.9 (207) | 5.0 ± 1.9 (141) |
Median | 8.0 | 17.5 | 12.0 | 4.6 |
Range | 3.5–25.5 | 6.2–36.1 | 0.9–41.0 |  |
Aneurysm neck, mm | Â | Â | Â | Â |
Mean ± SD (N) | 5.5 ± 1.4 (82) | 8.8 ± 4.3 (108) | 7.1 ± 4.2 (202) | 4.0 ± 1.4 (141) |
Median | 5.0 | 8.1 | 6.0 | 3.7 |
Range | 4.0–9.8 | 4.1–36.1 | 0.8–53.0 |  |
Aneurysm location | Â | Â | Â | Â |
ICA/PCoA, % (n/N) | 100 (82/82) | 100 (108/108) | 90.8 (188/207) | 95 (134/141) |
Multiple PEDs used, % (n/N) | 0.0 (0/82) | 98.1 (105/107) | 18.8 (39/207) | 6.4 (9/141) |
Efficacy endpoint | AMVR >35% as a proxy for angiographic occlusion | Angiographic occlusion | Angiographic occlusion | Angiographic occlusion |
